vs
MACROGENICS INC（MGNX）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
MACROGENICS INC的季度营收约是RBB Bancorp的1.3倍（$41.2M vs $32.3M），MACROGENICS INC同比增速更快（113.0% vs 12.6%），MACROGENICS INC自由现金流更多（$42.8M vs $42.6M），过去两年MACROGENICS INC的营收复合增速更高（112.8% vs 7.0%）
MacroGenics Inc是一家临床阶段生物制药公司，专注于研发针对癌症和自身免疫性疾病的新型免疫疗法，核心产品管线以单克隆抗体类治疗药物为核心，重点项目覆盖实体瘤与血液恶性肿瘤，通过与全球药企合作推进产品落地。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
MGNX vs RBB — 直观对比
营收规模更大
MGNX
是对方的1.3倍
$32.3M
营收增速更快
MGNX
高出100.5%
12.6%
自由现金流更多
MGNX
多$188.0K
$42.6M
两年增速更快
MGNX
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $32.3M |
| 净利润 | — | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -29.3% | 39.5% |
| 净利率 | — | 31.5% |
| 营收同比 | 113.0% | 12.6% |
| 净利润同比 | — | 132.1% |
| 每股收益（稀释后） | $-0.23 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGNXRBB
| Q4 25 | $41.2M | $32.3M | ||
| Q3 25 | $72.8M | $32.6M | ||
| Q2 25 | $22.2M | $35.8M | ||
| Q1 25 | $13.2M | $28.5M | ||
| Q4 24 | $19.4M | $28.7M | ||
| Q3 24 | $110.7M | $30.3M | ||
| Q2 24 | $10.8M | $27.5M | ||
| Q1 24 | $9.1M | $28.2M |
净利润MGNXRBB
| Q4 25 | — | $10.2M | ||
| Q3 25 | $16.8M | $10.1M | ||
| Q2 25 | $-36.3M | $9.3M | ||
| Q1 25 | $-41.0M | $2.3M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $56.3M | $7.0M | ||
| Q2 24 | $-55.7M | $7.2M | ||
| Q1 24 | $-52.2M | $8.0M |
毛利率MGNXRBB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 98.8% | — | ||
| Q3 24 | 99.8% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 97.0% | — |
营业利润率MGNXRBB
| Q4 25 | -29.3% | 39.5% | ||
| Q3 25 | 25.6% | 40.7% | ||
| Q2 25 | -165.3% | 36.1% | ||
| Q1 25 | -323.1% | 11.2% | ||
| Q4 24 | -273.0% | 17.6% | ||
| Q3 24 | 48.9% | 31.6% | ||
| Q2 24 | -538.9% | 35.6% | ||
| Q1 24 | -590.4% | 39.9% |
净利率MGNXRBB
| Q4 25 | — | 31.5% | ||
| Q3 25 | 23.1% | 31.2% | ||
| Q2 25 | -163.0% | 26.1% | ||
| Q1 25 | -311.1% | 8.0% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | 50.9% | 23.1% | ||
| Q2 24 | -515.6% | 26.4% | ||
| Q1 24 | -573.3% | 28.4% |
每股收益（稀释后）MGNXRBB
| Q4 25 | $-0.23 | $0.59 | ||
| Q3 25 | $0.27 | $0.59 | ||
| Q2 25 | $-0.57 | $0.52 | ||
| Q1 25 | $-0.65 | $0.13 | ||
| Q4 24 | $-0.24 | $0.26 | ||
| Q3 24 | $0.90 | $0.39 | ||
| Q2 24 | $-0.89 | $0.39 | ||
| Q1 24 | $-0.84 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.2M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $55.6M | $523.4M |
| 总资产 | $256.8M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资MGNXRBB
| Q4 25 | $57.2M | $212.3M | ||
| Q3 25 | $80.1M | $234.9M | ||
| Q2 25 | $130.7M | $191.9M | ||
| Q1 25 | $145.6M | $238.8M | ||
| Q4 24 | $182.8M | $257.7M | ||
| Q3 24 | $179.6M | $349.4M | ||
| Q2 24 | $83.9M | $252.8M | ||
| Q1 24 | $80.4M | — |
总债务MGNXRBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益MGNXRBB
| Q4 25 | $55.6M | $523.4M | ||
| Q3 25 | $67.0M | $514.3M | ||
| Q2 25 | $46.6M | $517.7M | ||
| Q1 25 | $79.1M | $510.3M | ||
| Q4 24 | $116.1M | $507.9M | ||
| Q3 24 | $120.1M | $509.7M | ||
| Q2 24 | $57.8M | $511.3M | ||
| Q1 24 | $106.2M | $514.0M |
总资产MGNXRBB
| Q4 25 | $256.8M | $4.2B | ||
| Q3 25 | $270.8M | $4.2B | ||
| Q2 25 | $245.4M | $4.1B | ||
| Q1 25 | $224.6M | $4.0B | ||
| Q4 24 | $261.7M | $4.0B | ||
| Q3 24 | $264.5M | $4.0B | ||
| Q2 24 | $201.1M | $3.9B | ||
| Q1 24 | $248.3M | $3.9B |
负债/权益比MGNXRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.0M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $42.8M | $42.6M |
| 自由现金流率自由现金流/营收 | 103.8% | 131.8% |
| 资本支出强度资本支出/营收 | 0.6% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | $-83.0M | $73.5M |
8季度趋势，按日历期对齐
经营现金流MGNXRBB
| Q4 25 | $43.0M | $43.4M | ||
| Q3 25 | $-30.2M | $2.1M | ||
| Q2 25 | $-47.0M | $21.7M | ||
| Q1 25 | $-46.9M | $7.8M | ||
| Q4 24 | $-38.4M | $58.5M | ||
| Q3 24 | $60.2M | $24.5M | ||
| Q2 24 | $-44.5M | $11.7M | ||
| Q1 24 | $-45.6M | $4.8M |
自由现金流MGNXRBB
| Q4 25 | $42.8M | $42.6M | ||
| Q3 25 | $-30.6M | $1.8M | ||
| Q2 25 | $-47.7M | $21.6M | ||
| Q1 25 | $-47.4M | $7.6M | ||
| Q4 24 | $-39.0M | $57.7M | ||
| Q3 24 | $59.6M | $24.2M | ||
| Q2 24 | $-45.5M | $11.5M | ||
| Q1 24 | $-47.1M | $4.7M |
自由现金流率MGNXRBB
| Q4 25 | 103.8% | 131.8% | ||
| Q3 25 | -42.0% | 5.4% | ||
| Q2 25 | -214.5% | 60.2% | ||
| Q1 25 | -359.5% | 26.7% | ||
| Q4 24 | -201.7% | 201.0% | ||
| Q3 24 | 53.8% | 80.0% | ||
| Q2 24 | -421.6% | 42.0% | ||
| Q1 24 | -517.4% | 16.6% |
资本支出强度MGNXRBB
| Q4 25 | 0.6% | 2.5% | ||
| Q3 25 | 0.6% | 1.1% | ||
| Q2 25 | 3.2% | 0.3% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 3.2% | 2.7% | ||
| Q3 24 | 0.5% | 0.8% | ||
| Q2 24 | 9.6% | 0.5% | ||
| Q1 24 | 16.0% | 0.5% |
现金转化率MGNXRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | -1.79× | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | 1.07× | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
RBB
暂无分部数据
